News
Bioiberica has been assigned to the A group, which corresponds to companies having their own R&D center and production plant, with a significant volume of research.The biotech company invests close to13% of its profits into R&D, and during 2013 they intend to begin marketing their personalized medicine range of products for osteoarthritis treatment.
On March 15th, Bioiberica held at the Colegio Oficial de Veterinarios of Seville, Spain, a scientific session on interesting future trends in immunology and immunomodulation
Bioiberica is rated good and remains within the A group, representing companies with significant research activity The Spanish chemical-pharmaceutical company, which employs 386 workers, has more than 58 R&D projects currently under development.
Condrovet Taste evolves: now it is sold in boxes of 40, 80, 120 or 140 capsules. This new package design replaces the old boxes of 60, 100, 140 or 240 capsules.
Bioiberica, always true to its commitment with research and scientific dissemination, opens up new technical content sections at www.bioiberica.es and veterinaria.bioiberica.es